Management team

 

Richard Bethell

Richard Bethell

Born: 1963. Title: Chief Scientific Officer.
Education: Doctor of Philosophy (D. Phil.) in chemistry from Oxford University. M.A. in Natural Sciences from Cambridge University.
Employed: 2013.
Background: Former head of Biological Sciences at Boehringer Ingelheim (Canada) Ltd., Head of Therapeutic Research at Shire and various positions at Pfizer and GlaxoSmithKline in the field of development and research.
Shares in Medivir: 8,887 class B.
Warrants in Medivir: 4,100.

 

ERIK BJÖRK

Born: 1976. Title: Chief Financial Officer.
Education: MSc in Finance from Lund University LLM from Lund University.
Employed: 2018.
Background: Former CFO for AstraZeneca Sweden Operations. Before that 11 years with Procter & Gamble, in global finance leadership positions in Switzerland, UK and Sweden. Founded and ran a management consultancy focusing on financial strategy and performance with clients within Life Sciences.
Shares in Medivir: 5,400 class B.
Warrants in Medivir: 6,150.

 

Daniel Eriksson

DANIEL ERIKSSON

Born: 1975. Title: Chief Information Officer.
Education: PhD from Coventry University, BSc in Systems Science from Linkoping University
Employed: 2016
Background: Former Technical Director for G4S Risk Management, India Country Manager for Hill & Associates, e-Governance advisor for Iraqi authorities, CIO for the UN OPS Kosovo mission, as well as a series of positions with the UN and international organisations in roles relating to IT, security, decision support systems, innovation, and digitalisation.
Shares in Medivir: 0
Warrants in Medivir: 4,100.

 

Christina Herder

CHRISTINA HERDER

Born: 1961. Title: Executive Vice President Strategic Business Development.
Education: Ph. D. in physical chemistry from Royal Institute of Technology and Executive MBA from Stockholm University.
Employed: 2017.
Background: Former CEO of Modus Therapeutics. Prior to that Director, Corporate Development in Sobi. Responsible to build and lead the function Project & Portfolio Management in Biovitrum. Also Member of the Boards of PCI Biotech and Idogen.
Shares in Medivir: 0.
Warrants in Medivir: 1,230.

 

Åsa Holmgren

ÅSA HOLMGREN

Born: 1965. Title: Executive Vice President Strategic Regulatory Affairs and Market Access.
Education: M. Sc. in Pharmacy, trained at Uppsala University.
Employed: 2015.
Background: Former Head of Regulatory Affairs at Orexo AB. Extensive experience from a number of large pharma­ceutical companies, including 12 years as Senior Global Regulatory Affairs Director at AstraZeneca, and, in particular, international, strategic duties within Regulatory Affairs. Åsa has also worked for AstraZeneca in Canada and Japan.
Shares in Medivir: 0.
Warrants in Medivir: 2,000.

 

Christine Lind

Christine Lind

Born: 1974. Title: President and CEO.
Education: B. Sc. Finance and Information Systems from New York University and Masters in Business Administration from Columbia Business School.
Employed: Joined Medivir in 2015 as EVP, Strategic Business Development.
Background: Previously Vice President, Business Development at LifeCell Corporation and 12 years of investment banking experience in biotech and pharma advisory and capital raising at Merrill Lynch & Co. and Gerard Klauer Mattison & Co.
Shares in Medivir: 37,066 class B.
Warrants in Medivir: 20,500.

 

John Öhd

John Öhd

Born: 1971. Title: Chief Medical Officer.
Education: MD from Linköping University, and PhD in Experimental Pathology from Lund University.
Employed: 2014
Background: Previously Medivir’s Director of Clinical R&D. Prior to joining Medivir he held a position as senior director of Experimental Medicine at Shire. John also worked in several positions at AstraZeneca in Södertalje, Sweden, including group director for early development in cognitive and neurodegenerative disorders. He worked in cancer research initially at Lund University where he received a PhD in Experimental Pathology and subsequently at Karolinska Institute. John received his MD from Linköping University, and trained clinically at Karolinska University Hospital.
Shares in Medivir: 0.
Warrants in Medivir: 2,000.

 

Page updated 16 February 2018